Gufic BioSciences Ltd - Feb 2025 Earnings Call Transcript Analysis

  ·   2 min read

Earnings Call Transcript Analysis Report #

Financial Performance #

Key Financial Metrics (Q3 FY25 vs Q3 FY24) #

  • Total Revenue from Operations: INR 207.8 crores (up from INR 201.8 crores).
    • Quote (CFO): “The total revenue for the operation for the financial year ‘24- ‘25 in Q3 is INR 207.8 crores compared to Q3 of financial year ‘23- ‘24 of INR 201.8 crores.”
  • EBITDA: INR 35.8 crores (down from INR 36.9 crores).
  • EBITDA Margin: 17.23% (down from 18.29%).
  • Profit Before Tax (PBT): INR 26.3 crores (down from INR 29.6 crores).
  • PBT Margin: 12.66% (down from 14.67%).
  • Profit After Tax (PAT): INR 19.4 crores (down from INR 22.3 crores).
  • PAT Margin: 9.34% (down from 11.05%).

Key Financial Metrics (9M FY25 vs 9M FY24) #

  • Total Revenue from Operations: INR 614.8 crores (slightly down from INR 616.7 crores).
  • EBITDA: INR 111.6 crores (slightly down from INR 112.9 crores).
  • EBITDA Margin: 18.15% (slightly down from 18.31%).
  • Profit Before Tax (PBT): INR 83.6 crores (down from INR 88.6 crores).
  • PBT Margin: 13.60% (down from 14.37%).
  • Profit After Tax (PAT): INR 61.9 crores (down from INR 66.1 crores).
  • PAT Margin: 10.07% (down from 10.72%).

Revised Guidance or Forecasts #

  • Indore facility expected to generate INR 6 crores in Q3 FY25, with Q4 FY25 revenue projected at INR 20 crores (CFO) or 2-3x of Q3 (CEO).
  • Indore facility FY26 revenue forecast: “minimum INR150 crores additional revenue” (CFO).
  • Margin pressure expected in the near term due to Indore start-up costs, with improvement anticipated post-FY26.
    • Quote (CFO): “after ‘26, when the capacity utilization of Indore will be picked up, I think that the EBITDA margin and PAT margin is going to improve after ‘26 onwards.”

Areas of Growth or Decline #

  • Revenue showed slight YoY growth for Q3 but was flat for 9M.
  • EBITDA, PBT, and PAT declined both YoY for Q3 and for the 9M period, with corresponding margin compression.